EAM
VTYX

Exome Asset Management’s Ventyx Biosciences VTYX Stock Holding History

Exome Asset Management’s Portfolio VTYX Stock Details VTYX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-60,600
Closed -$188K – 88
2025
Q3 		$188K Buy
+60,600
New +$161K 0.11% 66
2024
Q2 		– Sell
-163,922
Closed -$902K – 74
2024
Q1 		$902K Buy
+163,922
New +$750K 0.77% 47

Other funds holding VTYX

AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Exome Asset Management's VTYX Position: Q4 2025 in Review

Exome Asset Management sold out of Ventyx Biosciences (VTYX) in Q4 2025, closing a stake of 60,600 shares — an estimated $188K sold.

Exome Asset Management first reported a position in VTYX in Q1 2024 and held it in 2 quarters. The position peaked at $902K in Q1 2024. 139 funds tracked by Wall St. Rank hold VTYX as of Q4 2025.

  • Exome Asset Management reported no remaining Ventyx Biosciences position as of Q4 2025 after selling out during the quarter.
  • Exome Asset Management sold 60,600 Ventyx Biosciences shares in Q4 2025, an estimated $188K.
  • Exome Asset Management first reported a position in Ventyx Biosciences in Q1 2024 and held it in 2 quarters.
  • Exome Asset Management's Ventyx Biosciences position peaked at $902K in Q1 2024.
  • 139 funds tracked by Wall St. Rank held Ventyx Biosciences as of Q4 2025.

Based on Exome Asset Management's 13F filing for Q4 2025, filed 13 Feb 2026.